The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8+ T-cell responses: The immunological consequences of the biodistribution profile
暂无分享,去创建一个
Thomas Rades | Yvonne Perrie | Dennis Christensen | T. Rades | C. Foged | Y. Perrie | D. Christensen | K. Korsholm | P. Andersen | Peter Andersen | Swapnil Khadke | Camilla Foged | Swapnil Khadke | Signe Tandrup Schmidt | Karen Smith Korsholm | S. Schmidt
[1] A. Brooks,et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells , 2009, Nature Immunology.
[2] Remo Guidieri. Res , 1995, RES: Anthropology and Aesthetics.
[3] P. Andersen,et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. , 2005, Biochimica et biophysica acta.
[4] T. Allen,et al. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. , 1993, Biochimica et biophysica acta.
[5] P. Andersen,et al. A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells , 2009, PloS one.
[6] Yvonne Perrie,et al. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[7] K. Murphy,et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells , 2010, The Journal of experimental medicine.
[8] O. Joffre,et al. Cross-presentation by dendritic cells , 2012, Nature Reviews Immunology.
[9] P. Andersen,et al. High‐frequency vaccine‐induced CD8+ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection , 2014, European journal of immunology.
[10] Sang-Ho Kim,et al. Principles of , 2013 .
[11] U. Yrlid,et al. Lymph-borne CD 8 a þ dendritic cells are uniquely able to cross-prime CD 8 þ T cells with antigen acquired from intestinal epithelial cells , 2014 .
[12] R. Johnston,et al. Alphavirus-Adjuvanted Norovirus-Like Particle Vaccines: Heterologous, Humoral, and Mucosal Immune Responses Protect against Murine Norovirus Challenge , 2009, Journal of Virology.
[13] Yvonne Perrie,et al. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. , 2008, International journal of pharmaceutics.
[14] D. Tough,et al. Type I interferon as a stimulus for cross-priming. , 2008, Cytokine & growth factor reviews.
[15] S. Dow,et al. Efficient Immunization and Cross-Priming by Vaccine Adjuvants Containing TLR3 or TLR9 Agonists Complexed to Cationic Liposomes1 , 2006, The Journal of Immunology.
[16] N. Petrovsky,et al. Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.
[17] P. Stayton,et al. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[18] Henk C. Hoogsteden,et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.
[19] John J. Erickson,et al. Human Metapneumovirus Virus-Like Particles Induce Protective B and T Cell Responses in a Mouse Model , 2014, Journal of Virology.
[20] G. Belz,et al. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[21] H. M. Nielsen,et al. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[22] N. Valiante,et al. Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.
[23] J. Hubbell,et al. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. , 2013, Biomaterials.
[24] L. Jorgensen,et al. Protein Antigen Adsorption to the DDA/TDB Liposomal Adjuvant: Effect on Protein Structure, Stability, and Liposome Physicochemical Characteristics , 2012, Pharmaceutical Research.
[25] A. Iwasaki,et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection , 2009, The Journal of experimental medicine.
[26] Sai T Reddy,et al. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[27] F. Sánchez‐Madrid,et al. CD69 is an immunoregulatory molecule induced following activation. , 2005, Trends in immunology.
[28] Gabrielle T Belz,et al. Dendritic cells: driving the differentiation programme of T cells in viral infections , 2008, Immunology and cell biology.
[29] C. Kurts,et al. Cross-priming in health and disease , 2010, Nature Reviews Immunology.
[30] M. Swartz,et al. The physiology of the lymphatic system. , 2001, Advanced drug delivery reviews.
[31] D. Venzon,et al. TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection , 2011, The Journal of Immunology.
[32] G. Karupiah,et al. Cutting Edge: Conventional CD8α+ Dendritic Cells Are Generally Involved in Priming CTL Immunity to Viruses 1 , 2004, The Journal of Immunology.
[33] J. Ward,et al. A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. , 2004, Vaccine.
[34] R. Rappuoli,et al. The Intangible Value of Vaccination , 2002, Science.
[35] J. Ruberte,et al. Lymphatic drainage of Listeria inonocytogenes and Indian ink inoculated in the peritoneal cavity of the mouse , 1992, Laboratory animals.
[36] M. Bevan,et al. Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.
[37] P. Andersen,et al. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. , 2014, Vaccine.
[38] C. Foged,et al. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[39] Martin F. Bachmann,et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.
[40] P. Andersen,et al. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice , 2012, Cancer Immunology, Immunotherapy.
[41] F. Baneyx,et al. Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice. , 2014, Nanomedicine : nanotechnology, biology, and medicine.
[42] H. M. Nielsen,et al. Incorporation of the TLR4 Agonist Monophosphoryl Lipid A Into the Bilayer of DDA/TDB Liposomes: Physico-Chemical Characterization and Induction of CD8+ T-Cell Responses In Vivo , 2011, Pharmaceutical Research.
[43] R. Kroczek,et al. Lymph-borne CD8α+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells , 2014, Mucosal Immunology.
[44] J. Buer,et al. Immunization with Biodegradable Nanoparticles Efficiently Induces Cellular Immunity and Protects against Influenza Virus Infection , 2013, The Journal of Immunology.
[45] J. Ramsey,et al. The role of the lymphatic system in vaccine trafficking and immune response. , 2011, Advanced drug delivery reviews.
[46] Nicholas Collins,et al. Cutting Edge: CD69 Interference with Sphingosine-1-Phosphate Receptor Function Regulates Peripheral T Cell Retention , 2015, The Journal of Immunology.
[47] F. Zepp. Principles of vaccine design-Lessons from nature. , 2010, Vaccine.
[48] E. Unanue,et al. Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.
[49] G. Belz,et al. Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.
[50] B. Guy,et al. The perfect mix: recent progress in adjuvant research , 2007, Nature Reviews Microbiology.
[51] H. M. Nielsen,et al. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.